Você procurou por: drugs , and dangerous drugs in transit (Finlandês - Inglês)

this is a violent and dangerous planet.
this is a violent and dangerous planet.

emcdda (2007a), drugs and crime: a complex relationship, drugs in focus nro 16, euroopan huumausaineiden ja niiden väärinkäytön seurantakeskus, lissabon.
emcdda (2007a), drugs and crime: a complex relationship, drugs in focus no 16, european monitoring centre for drugs and drug addiction, lisbon.

studies to evaluate the safety of residues of veterinary drugs in human food:
studies to evaluate the safety of residues of veterinary drugs in human food:

emcdda (2007b), ”drugs and crime: a complex relationship”, drugs in focus, nro 16, euroopan huumausaineiden ja niiden väärinkäytön seurantakeskus, lissabon.
emcdda (2007b), ‘drugs and crime: a complex relationship’, drugs in focus no 16, european monitoring centre for drugs and drug addiction, lisbon.

muuten viittaan tässä yhteydessä instituuttiin nimeltä european monitoring center for drugs and drug addiction, emcdda.
in this context, i would also draw your attention to the european monitoring centre for drugs and drug addiction, the emcdda.

emcdda (2007c), drugs and driving, erityiskysymys, euroopan huumausaineiden ja niiden väärinkäytön seurantakeskus, lissabon.
emcdda (2007c), drugs and driving, selected issue, european monitoring centre for drugs and drug addiction, lisbon.

emcdda (2007), drugs and driving, selected issue, euroopan huumausaineiden ja niiden väärinkäytön seurantakeskus, lissabon.
emcdda (2007), drugs and driving, selected issue, european monitoring centre for drugs and drug addiction, lisbon.

emcdda (2007a): drugs and crime: a complex relationship, teemana huumeet, euroopan unionin julkaisutoimisto, luxemburg.
emcdda (2007a), drugs and crime: a complex relationship, drugs in focus, publications office of the european union, luxembourg.

emcdda (2008c): drugs and vulnerable groups of young people, emcdda:n erityiskysymys, euroopan unionin julkaisutoimisto, luxemburg.
emcdda (2008c), drugs and vulnerable groups of young people, emcdda selected issue, publications office of the european union, luxembourg.

teemana huumeet – drugs in focus on tilannekatsausten sarja, jota julkaisee euroopan huumausaineiden ja niiden väärinkäytön seurantakeskus (emcdda) lissabonissa.
drugs in focus is a series of policy briefings published by the european monitoring centre for drugs and drug addiction (emcdda), lisbon.

keski- ja itä-euroopan maiden kanssa on 10. maaliskuuta neuvoteltu työryhmässä" drugs and organised crime".
a meeting of the working party'drugs and organised crime ' was held with the central and eastern european countries on 10 march.

state company for drugs and medical appliances (alias a) general establishment for drugs & medical applicances, b) kimadia), osoite: mansour city, p.o. box 6138, bagdad, irak.
state company for drugs and medical appliances (alias (a) general establishment for drugs & medical applicances, (b) kimadia), address: mansour city, p.o. box 6138, baghdad, iraq.

tässä liitteessä "kasviperäisillä aineilla ja rohdosvalmisteilla" tarkoitetaan samaa kuin ilmauksella herbal drugs and herbal drug preparations, sellaisina kuin ne määritellään euroopan farmakopeassa.
for the purposes of this annex the terms "herbal substances and preparations" shall be considered equivalent to the terms "herbal drugs and herbal drug preparations", as defined in the european pharmacopoeia.

polyesteri ja etyylivinyyliasetaatti lääkeliimamatriksi (drug-in-adhesive, dia):
polyester and ethyl vinyl acetate

17alue kliininenkliininen kliininenkuvaus haitta-hyötyarvioinnin tueksi hakija sitoutuu lisäksi toimittamaan chmp: n tarkastettavaksi 48 viikon tehoa ja turvallisuutta koskevat tiedot vielä keskeneräisestä vaiheen iii tutkimuksesta 018 (a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and antiretroviral activity of mk-0518 in combination with an optimized background therapy (obt) , versus optimized background therapy alone, in hiv-infected patients with documented resistance to at least 1 drug in each of the 3 classes of licensed oral antiretroviral therapies) ja tutkimuksesta 019 (a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and antiretroviral activity of mk-0518 in combination with an optimized background therapy (obt) , versus optimized background therapy alone, in hiv-infected patients with documented resistance to at least 1 drug in each of the 3 classes of licensed oral antiretroviral therapies) .hakija sitoutuu toimittamaan chmp: lle yksityiskohtaiset spesifiset suunnitelmat resistenssitilanteen seuraamisesta tihein raportointivälein.
area clinicalclinical clinicaldescription to further support the benefit: risk assessment, the applicant commits to provide chmp with the 48-week safety and efficacy data from the ongoing phase iii protocol 018 (a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and antiretroviral activity of mk-0518 in combination with an optimized background therapy (obt) , versus optimized background therapy alone, in hiv-infected patients with documented resistance to at least 1 drug in each of the 3 classes of licensed oral antiretroviral therapies) and protocol 019 (a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and antiretroviral activity of mk-0518 in combination with an optimized background therapy (obt) , versus optimized background therapy alone, in hiv-infected patients with documented resistance to at least 1 drug in each of the 3 classes of licensed oral antiretroviral therapies) for review.the applicant commits to provide the chmp with detailed specific plans for monitoring of resistance with frequent reporting intervals.the applicant commits to provide the chmp with the full protocol for an observational post-authorisation safety study as specified in the rmp for assessment prior to study initiation.17due date study reports submission by:31-mar-200831-dec-2007